Self-sufficient generics industry preparing for the end of the LDC patent waiver. Sized from published research with a GCC and India lens, for buyers, suppliers and investors.
Self-sufficient generics industry preparing for the end of the LDC patent waiver. Published estimates normalised to 2025 range from USD 3.2 bn to USD 6.0 bn; the Consulting Wallah central estimate is USD 4.0 bn, growing at about 11% a year to USD 8.3 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.
Growth is driven by local manufacturers meet ~98% of domestic demand, up from under 10% in the early 1980s (TBS, Daily Star, BIDA); exports growing: USD 238.5 mn in FY2025-26 (+12%) and +40% in Q1 FY2026-27 (bdnews24); lDC TRIPS pharma waiver has allowed production of ~20% patented molecules without licence costs (Daily Star).
Context that matters for buyers and suppliers: Local companies meet about 98% of Bangladesh's medicine demand. 213 active pharmaceutical companies (BIDA); BAPI has over 150 member companies (TBS). Industry employs ~200,000 directly and ~300,000 indirectly. Bangladesh imports over 85% of APIs at ~USD 1.3 bn per year (BIDA); other sources say 97% of APIs imported.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 3.2 bn–USD 6.0 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| BIDA (Bangladesh Investment Development Authority) (2025) — country - Bangladesh total pharmaceutical market (government | USD 6 bn (page headline: '$6B pharma market size'; 'expected to surpass USD 6 billion by 2025') (2025) | — () | over 12% (projected) |
| The Business Standard (TBS) citing industry (2024-09) — country - domestic market | USD 3 bn+ (home market 'already surpassing the $3 billion milestone') (2024) | USD 6.5 bn ('over $6.5 billion before 2028') (2028) | — |
| The Daily Star (2025-08) — country - domestic market | USD 3.5 bn+ (domestic market 'worth more than $3.5 billion') (2025) | — () | — |
| bdnews24 (EPB/industry data) (2026-10) — country - domestic market in local currency | Tk 300 bn+ (local market grew from Tk 90 bn in 2010 to over Tk 300 bn, roughly tripled) (2026) | — () | — |
| BRAC EPL Research (Square Pharma equity note, IQVIA FY2025 data) (2025) — country - domestic market (IQVIA-based) | BDT 300+ bn annually (2025) | — () | — |
| Consulting Wallah central estimate | USD 4.0 bn (2025) | USD 8.3 bn (2032) | ~11% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: prescription and OTC pharmaceuticals, biologics and vaccines across hospital, retail and government channels. Excluded: medical devices, nutrition. Figures at ex-manufacturer vs retail prices differ by 20–40%, which explains part of the published range.
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| Square Pharmaceuticals | 17.4% | Square 2025 sales Tk 6,434 crore, +12.99% YoY | |
| Incepta Pharmaceuticals | 12.8% | ||
| Beximco Pharmaceuticals | 9.6% | ||
| Healthcare Pharmaceuticals | 7.7% | ||
| Renata | 5.8% | ||
| Eskayef (SK+F) | 4.9% | ||
| Opsonin Pharma | 4.7% | ||
| Aristopharma | 4.4% | ||
| Popular Pharmaceuticals | 4.1% | ||
| ACME Laboratories | 3.9% | ||
| ACI | 3.8% |
Source: BRAC EPL Research equity note citing IQVIA FY2025 - https://www.bracepl.com/investments/public/assets/research-new/1779530184-squrpharma_equity_note-final.pdf
| Segment | Share | Note | |
|---|---|---|---|
| Off-patent / generic | 80% | CPD estimate | |
| Still under patent | 20% | produced under LDC TRIPS waiver |
Source: The Daily Star, Aug 2025 - https://www.thedailystar.net/business/news/the-end-exemption-3953556
| Axis | Segment | Figure | Note |
|---|---|---|---|
| Export earnings by fiscal year (EPB) | FY2020-21 | USD 169.02 mn | |
| Export earnings by fiscal year (EPB) | FY2021-22 | USD 188.78 mn | |
| Export earnings by fiscal year (EPB) | FY2022-23 | USD 175.42 mn | down ~7% |
| Export earnings by fiscal year (EPB) | FY2023-24 | USD 205.48 mn | first time above USD 200 mn |
| Export earnings by fiscal year (EPB) | FY2024-25 | USD 213.2 mn | |
| Export earnings by fiscal year (EPB) | FY2025-26 | USD 238.5 mn | up ~12% |
| Export earnings by fiscal year (EPB) | Q1 FY2026-27 (Jul-Sep 2026) | USD 76.6 mn | up ~40% YoY from USD 54.54 mn |
Source: As listed under Sources.
| Country / region | Figure | Year | Source |
|---|---|---|---|
| Bangladesh domestic market | USD 3.5 bn+ | 2025 | The Daily Star |
| Bangladesh pharma exports | USD 238.5 mn | FY2025-26 | bdnews24 / EPB |
| Bangladesh annual API imports | USD 1.2 bn (Daily Star) / USD 1.3 bn (BIDA) | 2025 | The Daily Star; BIDA |
| Export destinations | 150+ countries (BIDA, TBS); 'over 160 countries' (Daily Star) | 2025 | BIDA; Daily Star |
Source: Sources as named; see Sources and method.
Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation
Opportunities we see: industry target of USD 500 mn export earnings by next fiscal year; 1% of a ~USD 400 bn global generics market would add ~USD 4 bn (BAPI, bdnews24); tBS cites targets of USD 450 mn exports in 2025 and USD 1.5 bn by 2030; aPI localisation: 200-acre BSCIC API park at Munshiganj with tax holidays to 2032 (BIDA).
| Date | Development | Source |
|---|---|---|
| 2026-10 | Pharma exports jump ~40% YoY in Jul-Sep 2026 to USD 76.6 mn; September alone almost USD 30 mn; industry targets USD 500 mn next fiscal year | bdnews24 |
| 2026-10 | Bangladesh scheduled to exit UN LDC list on 24 Nov 2026; government has applied for a three-year extension pending UNGA decision | bdnews24 |
| 2025-08 | FY2024-25 pharma exports reach USD 213 mn; debate over ending of TRIPS exemption; only 4 of 42 API park plots operational | The Daily Star |
| 2025 | IQVIA FY2025: Square leads with 17.4% share, Incepta 12.8%, Beximco 9.6%; Square turnover Tk 6,434 crore (+12.99%) | BRAC EPL Research |
| 2025 | Exports grew 3.46% YoY to USD 177.42 mn in first ten months of FY2024-25; export subsidies (6% pharma, 5% API) valid to 31 Dec 2025 | BIDA |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 3.2 bn to USD 6.0 bn. Consulting Wallah’s central estimate is USD 4.0 bn in 2025, rising to about USD 8.3 bn by 2032.
Published CAGRs range from 12% to 12%; our central case is about 11% a year to 2032.
Square Pharmaceuticals, Incepta Pharmaceuticals, Beximco Pharmaceuticals, Healthcare Pharmaceuticals, Renata PLC, Eskayef Pharmaceuticals (SK+F), Opsonin Pharma, Aristopharma among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.